The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Losing even a moderate amount of weight is associated with reduced progression of diabetes, improved blood pressure and HDL ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Full Frame Growth Partners is a minority investor in California-based Supergut, a company making powdered supplements and ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Weight loss medications and bariatric surgery used to be considered last-resort options, but now, they’re everywhere. More ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...

Decades of studies and statistics have shown that women are consistently held back in the workplace because of their gender.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...